Excreted Unchanged %
Hepatic
Half-Life (Normalesrd) Hours
2-4/Unchanged
Plasma Protein Binding %
99
Volume Of Distribution L/Kg
0.22-0.87
Dose For Normal Renal Function
100-600 mg q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
DeVane CL. Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med. 1994; 97: 13S-23S. [PMID: 7992822] / Ellingrod VL, Perry PJ. Nefazodone: a new antidepressant. Am J Health Syst Pharm. 1995; 52: 2799-812. [PMID: 8748566] / Goldberg RJ. Nefazodone and venlafaxine: two new agents for the treatment of depression. J Fam Pract. 1995; 41: 591-4. [PMID: 7500069] / Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 1995; 56 Suppl 6: 12-21. [PMID: 7649968]